Upstart Holdings reported Q2 results on August 4, and the stock's 9% weekly gain has done nothing to dislodge the bears — short interest has barely budged, analysts are raising targets, and the ORTEX short score is running near its highest level in months.
The short position here is genuinely large. Nearly 28% of Upstart's free float is sold short — roughly 26.9 million shares — and that number has climbed 3.6% over the past month. What's notable is that bears haven't flinched at the post-earnings bounce. Short interest was essentially flat week-on-week, ticking up just 0.3%, which tells you this isn't panic covering. The ORTEX short score of 74.2 reinforces that read: it has held in a tight band between 73 and 75 for the past two weeks, signalling sustained rather than episodic short pressure. The borrow market, however, offers no friction for the bears. Cost to borrow is a negligible 0.6%, and availability has loosened sharply — back to 77.6% from around 58% a week ago and well above the 52-week trough of 12.6%. Shares are easy and cheap to borrow. Squeeze mechanics are not in play here.
Options positioning adds a mildly defensive note that doesn't quite square with the stock's bullish week. The put/call ratio edged to 0.67, a modest premium to its 20-day average of 0.64 — roughly 1.3 standard deviations above the mean. That's not an extreme reading by any measure (the 52-week high is 0.98), but it does suggest some protection-buying is running alongside the rally. High-correlation peers tell a broadly similar story: gained 11.7% on the week and rose 10.2%, so Upstart's 9% move sits in line with a sector-wide lift rather than standing out as idiosyncratic strength.
The Street's post-earnings reaction is unambiguously constructive, though targets still sit well below where bulls were positioned earlier this year. Needham raised its target to $42 from $40 and Piper Sandler lifted to $51 from $46, both within the past 24 hours; BTIG reiterated its $43 Buy. The consensus mean now stands near $40.60, roughly 34% above the current $30.32 price. That gap looks large in isolation, but Citigroup's recent cut from $80 to $61 — even while maintaining Buy — is a reminder that the Street has been trimming ambitions on this name through the summer. Goldman Sachs kept its Neutral at $39, which neatly captures the tension: the Q2 origination volume story (48% year-over-year growth) is hard to argue with, but 2026 EBITDA margin visibility remains the bear case anchor. The PE multiple has compressed roughly 2.6 points over the past month to 9.3x, reflecting that margin anxiety more than anything in the revenue line.
Insider activity is tilted toward selling, though the volumes are modest and well-flagged. The most recent trade on record is a $456k sale by division president Sanjay Datta in early June. The CFO and Chief Legal Officer also sold smaller tranches in May. None of these are large relative to the float, and all carry low significance scores. On the institutional side, founder and CEO David Girouard remains the dominant holder at 12.3% of shares. Marshall Wace added roughly 2.7 million shares in Q1, making it one of the more material recent buyers — a hedge fund build worth watching as subsequent filings emerge.
The next earnings event isn't until November 3. Between now and then, the stock's trajectory will turn on whether the Q2 origination momentum translates into improving margin guidance — and whether that 27.6% short position, which hasn't moved despite a 9% bounce, eventually finds a reason to cover.
See the live data behind this article on ORTEX.
Open UPST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
